Actelion Close to Sealing Ceptaris Deal As U.S. Approves Drug

Actelion is one step closer to acquiring Ceptaris as the latter was granted FDA approval for its Valchlor gel, a topical treatment for a rare form of non-Hodkin’s lymphoma.
The Economic Times